Telix Granted FDA Approval for ZIRCON
Renal Cancer Imaging Study

Melbourne (Australia) – 23 January 2020. Telix Pharmaceuticals Limited (ASX: TLX) has today announced that the US Food and Drug Administration has approved the ZIRCON study for recruitment of American patients. The receipt of an Investigational New Drug (IND) notice of allowance will enable patient recruitment to commence in the United States in thirty (30) days.

The ZIRCON (Zirconium Imaging in Renal Cancer Oncology) is an international Phase III study to evaluate the utility of TLX250-CDx (\(^{89}\)Zr-girentuximab) for the imaging of clear cell renal cell cancer (ccRCC) using Positron Emission Tomography (PET). The study aims to recruit approximately 250 patients and is currently recruiting at 19 sites in Australia and Europe. The IND allowance in the US will add up to a further 6 leading cancer centres in the United States. The trial is expected to complete enrolment around mid-year.

Telix CEO Dr. Christian Behrenbruch said, “This IND is a major milestone for the company in terms of moving ahead the ZIRCON study as well as engagement with US regulators for a late-stage trial. We are excited to be adding US patients to the study. We’d also like to thank our North American manufacturing and pharmacy partners – Isologic and Cardinal Health – for their support with this submission.”

About Telix Pharmaceuticals Limited

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). The company is headquartered in Melbourne with international operations in Belgium, Japan and the United States. Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com.

Telix Corporate Contact

Dr Christian Behrenbruch  
Telix Pharmaceuticals Limited  
CEO  
Email: chris@telixpharma.com

Telix Investor Relations

Dr. David Cade  
Telix Pharmaceuticals Limited  
CBO and Head of Investor Relations  
Email: david.cade@telixpharma.com

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “US Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This release has been authorised by Christian P. Behrenbruch, CEO of Telix Pharmaceuticals Limited.